Richmond, Va.-based VCU Health’s Massey Comprehensive Cancer Center has become the first facility in Virginia to offer tumor-infiltrating lymphocyte therapy for advanced stage melanoma patients.
TIL therapy is approved to treat the about 40% of patients with aggressive melanoma who do not respond to current treatment options, according to an Aug. 18 news release from the health system.
To administer the therapy, a sample of a patients’ tumor is removed and sent to a separate facility where tumor-infiltrating lymphocyte cells are extracted, “amplified and rejuvenated by the billions,” the news release said.
The immune cells are then returned to Massey and administered to the patient through a one-time infusion.
“We have recruited and trained a high-performing clinical team that operates like the Avengers against late-stage melanoma,” John McCarty, MD, medical director of Massey’s Cellular Immunotherapies and Transplant Program, said in the release. “We’re moving into a completely new era of cellular therapy.”
At the Becker's Perioperative Summit, taking place September 14–15 in Chicago, perioperative leaders and healthcare executives will focus on improving operating room efficiency, enhancing patient safety, optimizing staffing and driving innovation across surgical services. Apply for complimentary registration now.
